The estimated Net Worth of Ralph Dr. Kern is at least $885 Thousand dollars as of 24 December 2019. Ralph Kern owns over 3,000 units of Brainstorm Cell Therapeutics stock worth over $32,383 and over the last 8 years he sold BCLI stock worth over $0. In addition, he makes $852,145 as President and Chief Medical Officer at Brainstorm Cell Therapeutics.
Ralph has made over 1 trades of the Brainstorm Cell Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of BCLI stock worth $11,640 on 24 December 2019.
The largest trade he's ever made was buying 3,000 units of Brainstorm Cell Therapeutics stock on 24 December 2019 worth over $11,640. On average, Ralph trades about 333 units every 0 days since 2017. As of 24 December 2019 he still owns at least 115,655 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of Ralph Kern stock trades at the bottom of the page.
Dr. Ralph Kern serves as President, Chief Medical Officer of the Company. Dr. Kern was Senior Vice President, Head Worldwide Medical at Biogen Inc. since 2016. Prior positions at Biogen Inc. include Vice President, Head of Global Therapeutic Areas from 2015 to 2016 and Vice President, Head of Global Medical Neurology in 2015. Dr. Kern has also served Novartis Pharmaceuticals Corporation as Vice President, Head Neuroscience Medical Unit from 2014 to 2015 and as Vice President, Head MS Medical Unit from 2011 to 2014. He also worked for Genzyme Corporation from 2006 to 2011 where he served as Global Medical Director, Personalized Genetic Health (2010-2011), Head of Medical Affairs, Canada (2006-2008), General Manager, Fabry Disease (2008-2010) and Head of Medical Affairs, Canada (2006-2008). He also served as University Neurology Program Director at the University of Toronto (2003-2006), Consultant Neurologist at Mount Sinai Hospital (2001-2006) and Director, EMG, EEG and Evoked Potential Laboratory at The Credit Valley Hospital (1988-2001).
As the President and Chief Medical Officer of Brainstorm Cell Therapeutics, the total compensation of Ralph Kern at Brainstorm Cell Therapeutics is $852,145. There are 2 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.
Ralph Kern is 62, he's been the President and Chief Medical Officer of Brainstorm Cell Therapeutics since 2020. There are 3 older and 15 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
Ralph's mailing address filed with the SEC is C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF THE AMERICAS, 28TH FLOOR, NEW YORK, NY, 10019.
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, and International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include: